Aequus Pharmaceuticals Stock Target Price
AQS Stock | CAD 0.01 0.01 100.00% |
Aequus Pharmaceuticals fundamentals help investors to digest information that contributes to Aequus Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Aequus Stock. The fundamental analysis module provides a way to measure Aequus Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aequus Pharmaceuticals stock.
Aequus | Target Price |
Aequus Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Aequus Pharmaceuticals from analyzing Aequus Pharmaceuticals' financial statements. These drivers represent accounts that assess Aequus Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Aequus Pharmaceuticals' important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 10.1M | 11.2M | 14.8M | 4.6M | 3.3M | 3.2M | |
Enterprise Value | 11.8M | 11.8M | 14.6M | 5.2M | 8.2M | 14.6M |
Aequus Fundamentals
Return On Equity | -15.7 | ||||
Return On Asset | -1.58 | ||||
Operating Margin | (4.15) % | ||||
Current Valuation | 7.84 M | ||||
Shares Outstanding | 132.63 M | ||||
Shares Owned By Insiders | 14.68 % | ||||
Number Of Shares Shorted | 625 | ||||
Price To Earning | (1.85) X | ||||
Price To Book | 24.39 X | ||||
Price To Sales | 3.21 X | ||||
Revenue | 254.9 K | ||||
Gross Profit | 2.69 M | ||||
EBITDA | (2.68 M) | ||||
Net Income | (2.96 M) | ||||
Cash And Equivalents | 1.46 M | ||||
Cash Per Share | 0.02 X | ||||
Total Debt | 5.06 M | ||||
Debt To Equity | 248.30 % | ||||
Current Ratio | 4.37 X | ||||
Book Value Per Share | (0.05) X | ||||
Cash Flow From Operations | (2.29 M) | ||||
Short Ratio | 0.02 X | ||||
Earnings Per Share | (0.01) X | ||||
Target Price | 2.52 | ||||
Beta | -0.013 | ||||
Market Capitalization | 1.33 M | ||||
Total Asset | 1.09 M | ||||
Retained Earnings | (32.68 M) | ||||
Working Capital | (4.36 M) | ||||
Net Asset | 1.09 M |
About Aequus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aequus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aequus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aequus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aequus Stock Analysis
When running Aequus Pharmaceuticals' price analysis, check to measure Aequus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aequus Pharmaceuticals is operating at the current time. Most of Aequus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aequus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aequus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aequus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.